Valeant, Actavis Attractive – Deal or No Deal

Rumored merger talks between Valeant Pharmaceuticals and Actavis have reportedly stopped. However, both stocks look cheap on their own merits.

The rumored marriage between drug makers Valeant Pharmaceuticals International and Actavis would be one of the biggest deals so far this year in the health-care sector.

On Monday, shares of Valeant (ticker: VRX) rose 4.2% to $76.24, while shares of Actavis (ACT), formerly known as Watson Pharmaceuticals, rose 4.5% to $105.51, even as reports circulated that Valeant's bid to buy Actavis for over $13 billion in stock was put on hold...